Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (144)	8/10/2001 12:57:11 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 164

Synsorb Transfers 100,106 Oncolytics Shrs To Roseworth Dow Jones Newswires CALGARY -- Synsorb Biotech Inc. (SYBB) has transferred 100,106 shares of Oncolytics Biotech Inc. (T.ONC) to Roseworth Group LLC, for net proceeds of C$842,273. In a news release, the company said the share transfer, at an average of C$8.41 a share, is part of a previously announced equity line agreement with Roseworth under which Synsorb agreed to sell up to 1 million Oncolytics shares over a 12-month period. Synsorb said the number of shares issued in the first transfer represent less than 1.5% of its total Oncolytics holdings. The company said "meeting our cash requirements through the sale of Oncolytics shares is a non-dilutive and attractive means of funding our ongoing Phase III clinical trials for SYNSORB Cd." Synsorb said it now owns 6,649,894 shares of Oncolytics. Roseworth is a British Virgin Island company involved in investing in publicly traded equity securities for its own account. Synsorb is a pharmaceutical company. Oncolytics is a biotechnology company. Company Web Site: synsorb.com